Drug intelligence / Profile preview

NBG-046

Development stage: Unknown
Lead developer: NB Health Laboratory
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NBG-046 is a monoclonal antibody developed by NB Health Laboratory for the treatment of metabolic diseases. Its mechanism of action is as a G-protein coupled receptor (GPCR) antagonist, targeting GPCRs involved in metabolic and endocrine pathways. The drug is currently in the discovery phase and has not yet entered clinical trials or received regulatory approval. Its primary therapeutic area is endocrinology and metabolic disease, with an active indication for unspecified metabolic diseases[1][2][4].

Beyond the preview

Go deeper on NBG-046.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBG-046.

Explore the full profile